197 related articles for article (PubMed ID: 1527858)
1. Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release.
Berger EA; Sisler JR; Earl PL
J Virol; 1992 Oct; 66(10):6208-12. PubMed ID: 1527858
[TBL] [Abstract][Full Text] [Related]
2. Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events.
Thali M; Furman C; Helseth E; Repke H; Sodroski J
J Virol; 1992 Sep; 66(9):5516-24. PubMed ID: 1501286
[TBL] [Abstract][Full Text] [Related]
3. Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function.
Chiou SH; Freed EO; Panganiban AT; Kenealy WR
AIDS Res Hum Retroviruses; 1992 Sep; 8(9):1611-8. PubMed ID: 1457207
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like region in membrane fusion.
Berger EA; Lifson JD; Eiden LE
Proc Natl Acad Sci U S A; 1991 Sep; 88(18):8082-6. PubMed ID: 1896455
[TBL] [Abstract][Full Text] [Related]
5. CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion.
Broder CC; Berger EA
J Virol; 1993 Feb; 67(2):913-26. PubMed ID: 8419649
[TBL] [Abstract][Full Text] [Related]
6. Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus.
Bergeron L; Sullivan N; Sodroski J
J Virol; 1992 Apr; 66(4):2389-97. PubMed ID: 1548769
[TBL] [Abstract][Full Text] [Related]
7. Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope.
Willey RL; Theodore TS; Martin MA
J Virol; 1994 Jul; 68(7):4409-19. PubMed ID: 7515973
[TBL] [Abstract][Full Text] [Related]
8. Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity.
Page KA; Stearns SM; Littman DR
J Virol; 1992 Jan; 66(1):524-33. PubMed ID: 1727497
[TBL] [Abstract][Full Text] [Related]
9. Vaccinia virus vectors for study of membrane fusion mediated by human immunodeficiency virus envelope glycoprotein and CD4.
Ashorn P; Berger EA; Moss B
Methods Enzymol; 1993; 221():12-8. PubMed ID: 8361369
[No Abstract] [Full Text] [Related]
10. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.
Wyatt R; Sullivan N; Thali M; Repke H; Ho D; Robinson J; Posner M; Sodroski J
J Virol; 1993 Aug; 67(8):4557-65. PubMed ID: 8331723
[TBL] [Abstract][Full Text] [Related]
11. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
[TBL] [Abstract][Full Text] [Related]
12. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
Wyatt R; Thali M; Tilley S; Pinter A; Posner M; Ho D; Robinson J; Sodroski J
J Virol; 1992 Dec; 66(12):6997-7004. PubMed ID: 1279195
[TBL] [Abstract][Full Text] [Related]
13. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity.
LaBranche CC; Hoffman TL; Romano J; Haggarty BS; Edwards TG; Matthews TJ; Doms RW; Hoxie JA
J Virol; 1999 Dec; 73(12):10310-9. PubMed ID: 10559349
[TBL] [Abstract][Full Text] [Related]
14. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.
Yonezawa A; Hori T; Takaori-Kondo A; Morita R; Uchiyama T
J Virol; 2001 May; 75(9):4258-67. PubMed ID: 11287575
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.
Grimaila RJ; Fuller BA; Rennert PD; Nelson MB; Hammarskjöld ML; Potts B; Murray M; Putney SD; Gray G
J Virol; 1992 Apr; 66(4):1875-83. PubMed ID: 1548744
[TBL] [Abstract][Full Text] [Related]
16. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity.
Foda M; Harada S; Maeda Y
Microbiol Immunol; 2001; 45(7):521-30. PubMed ID: 11529558
[TBL] [Abstract][Full Text] [Related]
17. Cell fusion mediated by interaction of a hybrid CD4.CD8 molecule with the human immunodeficiency virus type 1 envelope glycoprotein does occur after a long lag time.
Golding H; Blumenthal R; Manischewitz J; Littman DR; Dimitrov DS
J Virol; 1993 Nov; 67(11):6469-75. PubMed ID: 8411350
[TBL] [Abstract][Full Text] [Related]
18. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.
Fenouillet E; Miquelis R; Drillien R
Virology; 1996 Apr; 218(1):224-31. PubMed ID: 8615025
[TBL] [Abstract][Full Text] [Related]
19. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4.
Cho MW; Lee MK; Carney MC; Berson JF; Doms RW; Martin MA
J Virol; 1998 Mar; 72(3):2509-15. PubMed ID: 9499115
[TBL] [Abstract][Full Text] [Related]
20. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.
Hart TK; Kirsh R; Ellens H; Sweet RW; Lambert DM; Petteway SR; Leary J; Bugelski PJ
Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2189-93. PubMed ID: 2006155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
